These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33496720)

  • 21. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.
    García-González MJ; Aldea Perona A; Lara Padron A; Morales Rull JL; Martínez-Sellés M; de Mora Martin M; López Díaz J; López Fernandez S; Ortiz Oficialdegui P; Jiménez Sosa A
    ESC Heart Fail; 2021 Dec; 8(6):4820-4831. PubMed ID: 34716753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 28. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
    Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
    Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimendan and Continuous Outpatient Support With Inotropes in Patients With Advanced Heart Failure: A Single-Centre Descriptive Study.
    Yeung T; Dagan M; Lankaputhra M; Cieslik L; Warner V; Leet A; Hare JL; Bergin P; Taylor AJ; Kaye DM; Patel HC
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):583-592. PubMed ID: 34983918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan.
    Mason P
    Intensive Crit Care Nurs; 2003 Dec; 19(6):370-1. PubMed ID: 14637297
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Shang G; Yang X; Song D; Ti Y; Shang Y; Wang Z; Tang M; Zhang Y; Zhang W; Zhong M
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):453-463. PubMed ID: 28597399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is levosimendan effective in paediatric heart failure and post-cardiac surgeries?
    Angadi U; Westrope C; Chowdhry MF
    Interact Cardiovasc Thorac Surg; 2013 Oct; 17(4):710-4. PubMed ID: 23832921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
    Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan: from basic science to clinical practice.
    Parissis JT; Rafouli-Stergiou P; Paraskevaidis I; Mebazaa A
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    Papp Z; Agostoni P; Alvarez J; Bettex D; Bouchez S; Brito D; Černý V; Comin-Colet J; Crespo-Leiro MG; Delgado JF; Édes I; Eremenko AA; Farmakis D; Fedele F; Fonseca C; Fruhwald S; Girardis M; Guarracino F; Harjola VP; Heringlake M; Herpain A; Heunks LMA; Husebye T; Ivancan V; Karason K; Kaul S; Kivikko M; Kubica J; Masip J; Matskeplishvili S; Mebazaa A; Nieminen MS; Oliva F; Papp JG; Parissis J; Parkhomenko A; Põder P; Pölzl G; Reinecke A; Ricksten SE; Riha H; Rudiger A; Sarapohja T; Schwinger RHG; Toller W; Tritapepe L; Tschöpe C; Wikström G; Lewinski DV; Vrtovec B; Pollesello P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):4-22. PubMed ID: 32639325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
    Silvetti S; Nieminen MS
    Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
    Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levosimendan: from basic science to clinical trials.
    Rognoni A; Lupi A; Lazzero M; Bongo AS; Rognoni G
    Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):9-15. PubMed ID: 21208157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.